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The integrity of the vascular endothelium of the blood-brain barrier (BBB) is central to cerebrovascular homeostasis. Given
the function of the BBB as a physical and metabolic barrier that buﬀers the systemic environment, oxidative damage to the
endothelial monolayer will have signiﬁcant deleterious impact on the metabolic, immunological, and neurological functions
of the brain. Glutathione (GSH) is a ubiquitous major thiol within mammalian cells that plays important roles in antioxidant
defense, oxidation-reduction reactions in metabolic pathways, and redox signaling. The existence of distinct GSH pools within
the subcellular organelles supports an elegant mode for independent redox regulation of metabolic processes, including those
that control cell fate. GSH-dependent homeostatic control of neurovascular function is relatively unexplored. Signiﬁcantly, GSH
regulation of two aspects of endothelial function is paramount to barrier preservation, namely, GSH protection against oxidative
endothelial cell injury and GSH control of postdamage cell proliferation in endothelial repair and/or wound healing. This paper
highlights our current insights and hypotheses into the role of GSH in cerebral microvascular biology and pathobiology with
special focus on endothelial GSH and vascular integrity, oxidative disruption of endothelial barrier function, GSH regulation of
endothelial cell proliferation, and the pathological implications of GSH disruption in oxidative stress-associated neurovascular
disorders, such as diabetes and stroke.
1. GlutathioneandNeurovascularHomeostasis
1.1.FunctionoftheBlood-BrainBarrier. Centraltoneurovas-
cular homeostasis is the function of the blood-brain barrier
(BBB). The BBB is a highly regulated interface between the
systemic circulation and brain parenchyma and is comprised
of a monolayer of brain capillary endothelial cells on the
blood side and perivascular cells on the brain side of
microvessels. The BBB functions to protect the parenchymal
cells from ﬂuctuations in plasma composition, such as
during exercise and following meals, and against circulating
neurotransmitters or xenobiotics capable of disrupting neu-
ral function [1]. In this regard, the BBB acts as a mechanical
barrier; brain capillaries are ∼50–100 times tighter than
peripheral microvessels, a property that is attributed to
intercellulartightjunctionsbetweenneighboringendothelial
cells that restrict the paracellular diﬀusion of hydrophilic
solutes. Only small molecules such as oxygen and CO2 can
freelydiﬀuseacrossthelipidmembranesoftheendothelium.
On the luminal and abluminal membranes, speciﬁc
transport systems regulate the transcellular traﬃco fs m a l l
hydrophilic molecules, such as GLUT-1 and L-system carrier
1 in the transport of glucose or leucine, respectively, thereby
providingaselective“transportbarrier”thatfacilitatesnutri-
ent entry [2]. The highly expressed P-glycoprotein trans-
porteronendothelialluminalsurfaceprotectsthebrainfrom
xenobiotics and the potentially toxic neurometabolite, glu-
tamate. In addition, an enrichment of endothelial degrada-
tive enzymes serves as an enzymatic barrier. Examples
include ectoenzymes such as peptidases and nucleotidases,
which metabolize peptides and ATP, respectively, and the
intracellular enzymes monoamine oxidase and cytochrome
P450 1A and 2B which inactivate blood-borne neuroactive
compounds. Moreover, the cerebral endothelium exhibits2 International Journal of Cell Biology
speciﬁc systems for receptor-mediated and adsorptive endo-
cytosis that allow for the transfer of speciﬁc peptides and
lipoproteins to the brain [2]. Such multiple functions of the
BBB regulate the brain microenvironment and maintain
parenchymal homeostasis.
1.2. Glutathione Redox System and Cellular Function. The
glutathione/glutathione disulﬁde (GSH/GSSG) couple is the
most abundant thiol redox system that plays a key role in
the maintenance of the redox environment in cells [3, 4].
Under physiological conditions, intracellular GSH home-
ostasis depends on de novo GSH synthesis, GSH redox
cycling, and transmembrane GSH transport. Cellular GSH
exists mainly in the reduced form with GSSG constituting
lessthan10%ofthetotalGSHpool.Thebiologicalfunctions
ofGSHareattributed to its unique γ-glutamylbond between
the glutamate and cysteine residues and to the presence of a
free thiol group. Reduced GSH is synthesized in the cytosol
in two steps from its constituent amino acids (glutamate,
cysteine, glycine) catalyzed by γ-glutamyl cysteine ligase
(GCL) and GSH synthase [5]. GCL catalyzes the formation
of γ-glutamylcysteine, the ﬁrst and rate-limiting reaction
in GSH synthesis, and enzyme function is controlled by
GSH feedback inhibition or by transcriptional upregulation
of enzyme subunits (Section 1.4). An important aspect of
cellular GSH homeostasis is that increased GSH oxidation is
generally followed by increases in the total pool size, notably
through enhanced de novo GSH synthesis.
The versatility of GSH in contributing to a myriad of
cellular functions is notable in its role in detoxication reac-
tions (e.g., hydroperoxide and xenobiotic catabolism), reg-
ulation of amino acid transport into cells, maintenance
of native three-dimensional protein structure in biosyn-
thetic/metabolic processes (e.g., prostaglandins D2 and E2
synthesis), serving as a cofactor for enzyme systems (e.g.,
glyoxalase I), and redox signaling. Thiol-disulﬁde exchanges
andproteinS-glutathiolationaremechanismsbywhichGSH
modulates the oxidative modiﬁcation of redox active cys-
teines within proteins and thereby regulates the activity of
a variety of enzyme functions, including those controlling
proliferation, diﬀerentiation, or apoptosis [6, 7].
1.2.1. Subcellular Distribution of GSH. Intracellular GSH is
diﬀerentially distributed among the various subcellularcom-
partments of cytosol, mitochondria, endoplasmic reticulum,
and nucleus wherein distinct redox pools are formed [8, 9].
Cytosolic GSH is highly reduced, and under physiological
conditions cytosolic GSH concentrations are between 1 and
11mM with the GSH to GSSG ratio maintained in excess
of 10 to 1 depending on cell types [10]. The redox state of
a cell is generally represented by the ratio of GSH to GSSG
given the large GSH pool size. Quantitatively, the cytosolic
pool accounts for >70% of the total cellular GSH, while
the nuclear and mitochondrial compartments comprise 10%
to 30% of the total cellular GSH, respectively [11]. The
uniqueness of the nuclear and mitochondrial GSH pools
is evidenced by the diﬀerences in compartmental GSH
turnover rate and sensitivity to chemical depletion [9].
Speciﬁcally, the distinct characteristic of the nuclear GSH
redox state is consistent with its physiological role in the nu-
cleus, signiﬁcantly during cell cycle [12]( Section 3.2 below).
Indeed, increased nuclear-to-cytosol GSH distribution is a
crucial factor in cell proliferation wherein elevated nuclear
GSHmaintainsthefunctionalintegrityofthenucleusingene
transcription [13].
While the biological importance of metabolically unique
GSH compartments in redox regulation of various endothe-
lial cell functions [14, 15] is yet to be fully deﬁned, it can be
readily appreciated that such independent GSH pools would
aﬀord an elegant mechanism for speciﬁc control of redox-
sensitive metabolic processes, the failure of which will have
signiﬁcant implications for endothelial pathobiology. The
reader is referred to previous excellent reviews for a full dis-
cussion of redox compartmentation and its integration in
redox signaling [3, 8, 15].
1.2.2. GSH in Cellular ROS and Redox Signaling. One of
the undesired consequences for an organism living in an
aerobic environment is an increased potential for oxidative
damage by reactive oxygen species (ROS). However, the
ability to thrive within such an aerobic environment also
implies an evolved capability to handle ROS-mediated tissue
damage [16]. The major intracellular sources of ROS,
namely, superoxide anion (O2
•−), hydrogen peroxide
(H2O2), or hydroxyl radical (HO
•), are derived from mito-
chondrial respiration, arachidonic acid pathway, and activ-
ities of cellular oxidases, such as cytochrome P450, glucose
oxidase, amino acid oxidases, xanthine oxidase, NADH/
NADPH oxidases, or NO synthases [17, 18]. ROS derived
fromxenobioticmetabolismorUV/γ-radiationareexamples
of exogenous sources. Elevated ROS levels are damaging
to cellular macromolecules like proteins, lipids, and DNA
and will induce a state of oxidative stress and redox imbal-
ance [8]. Central to maintaining intracellular redox bal-
ance is GSH-dependent ROS elimination that includes
GSHperoxidase-catalyzedhydroperoxidemetabolism,GSSG
reductase-catalyzed, NADPH-dependent GSH regeneration,
orGSHS-transferase-catalyzedxenobiotic detoxication [19].
The recognition that ROS can serve as important
mediators of cell signaling and that signal transduction
may be mediated by ROS-induced GSH redox imbalance
is major conceptual breakthrough in our understanding
of GSH-dependent redox signaling [20, 21]. Signiﬁcantly,
low ROS levels participate in the signaling of proliferation,
senescence, and apoptosis. For instance, H2O2-targeted pro-
teins containing redox sensitive cysteine residues (P-SH)
can result in the formation of reversible sulfenic (P-SOH)
as well as irreversible sulﬁnic (P-SO2H), and sulfonic (P-
SO3H) acid derivatives [22, 23]. The protein sulfenic acid
derivative can further react with nitric oxide (NO) to yield
nitrosothiol (P-SNO) or with another P-SH to form a
disulﬁde bond (P-SS-P) [22, 23]. The latter posttranslational
modiﬁcation, termed S-glutathiolation (also known as S-
glutathiolation), refers to the formation of a mixed disulﬁde
between the cysteine of GSH and a cysteine moiety of a
protein[6].ReversibleproteincysteineoxidationandproteinInternational Journal of Cell Biology 3
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Figure 1: Mechanisms of MG-mediated endothelial barrier dysfunction and its protection by GSH. MG-induced endothelial barrier
dysfunction can be caused by MG-protein crosslinking (glycation) resulting in the formation of MG-protein adducts, such as tight junction
occludin and basement membrane type IV collagen. MG-protein glycation can also modify the proteasomal and chaperone functions. ROS
generated during protein glycation can further mediate barrier dysfunction through various pathways: (a) increased intracellular [Ca2+],
(b) direct disruption of adherens junction and tight junction, or (c) phosphorylation of myosin light chain kinase and altered endothelial
cell contraction. Protection of barrier integrity is mediated by GSH, which functions as a cofactor in glyoxalase I-catalyzed metabolism of
MG. MG: methylglyoxal, GSH: reduced glutathione, O2
•−: superoxide anion, H2O2: hydrogen peroxide, ROS: reactive oxygen species, AJ:
adherens junction, TJ: tight junction, MLCK: myosin light chain kinase.
mixed disulﬁde formation are catalyzed by the thioredoxin
(Trx) and glutaredoxin (Grx) family of redox proteins
[6]. This GSH-protein cysteine interaction protects against
irreversible protein thiol oxidation and is an important
redox mechanism in regulating protein function at low or
modest levels of ROS [6]. ROS-dependent protein cysteine
oxidation has been implicated in the redox regulation of
a wide range of protein functions including enzyme activ-
ity, protein expression and abundance, subcellular protein
localization, and interaction with other molecular partners
in controlling new patterns of cell signaling and gene
expression. Viewed simply, control of protein functions by
reversible S-glutathiolation/deglutathiolation is akin to that
of phosphorylation/dephosphorylation.
1.3. Endothelial GSH and S-Glutathiolation in the Control of
Vascular Integrity. GSH exerts profound eﬀects on vascular
endothelial function, which include endothelial barrier per-
meability [24], cell apoptosis [25], chemotaxis, angiogenesis
[26,27],constitutiveandagonist-inducedadhesionmolecule
expression [28], leukocyte-endothelial adhesion response
[29], and endothelial dependent vasodilation [28, 30]. The
modulatory eﬀects of GSH are accomplished through the
scavenging of ROS [31], an important second messenger in
many endothelial functions. For instance, GSH was shown
to attenuate H2O2-induced decrease in transendothelial
electrical resistance via negative regulation of the activation
of p38 MAP kinase [24]. In other roles, reduced GSH acts
as a substrate for the detoxication enzymes, GSH peroxidase,
and GSH S-transferase. Our recent studies showed that GSH
served as a cofactor in glyoxalase 1-catalyzed detoxication of
methylglyoxal and prevented carbonyl stress-induced brain
endothelial barrier dysfunction (Figure 1).
A large body of evidence supports a role for S-
glutathiolation in redox regulation of vascular function,
ranging from cell signaling, apoptosis, protein folding, to
cytoskeletal reorganization. In hypertensive vessels, the thi-
olation of endothelial nitric oxide synthase (eNOS) is pivotal
in the redox control of vascular tone. The bioactive nitric
oxide (NO) molecule plays a crucial role in normal endothe-
lial function, including modulation of vascular dilator tone,
inhibition of platelet activation, inhibition of leukocyte
adhesion and migration, and inhibition of smooth muscle
cell migration and proliferation [32]. Therefore, altered NO
production, such as during oxidative stress, would compro-
mise vascular homeostasis. Oxidative stress has been shown
to mediate S-glutathiolation of eNOS that was associated
with decreased NOS activity, attenuated NO production,
increased O2
•− generation, and impaired endothelium-
dependent vasodilation, dysregulated processes that were
restored by thiol-speciﬁc reducing agents [33]. As for cell
signaling, oxidants have been shown to trigger direct S-
glutathiolation of p21ras at Cys118, which activated p21ras
and mediated downstream phosphorylation of ERK and
AKT in both endothelial and smooth muscle cells [34, 35].
Similarly, oxidant-induced insulin resistance was mediated
through S-glutathiolation of p21ras and ERK-dependent
inhibition ofinsulinsignaling [36].During diamide-induced
oxidative stress, activation of endothelial Ca2+ signaling
was associated with S-glutathiolation of the inositol-1,4,5-
trisphosphate (IP3) receptor (IP3R) and the plasmalemmal
Ca2+-ATPase pump, which promoted Ca2+ release from IP3-
sensitiveinternalCa2+ storesandelevatedbasal[Ca2+]iinthe
absence of extracellular Ca2+ [37].
Current evidence implicates the involvement of S-
glutathiolation/deglutathiolation in apoptotic signaling. In4 International Journal of Cell Biology
TNF-α-mediated apoptosis, Grx-catalyzed deglutathiolation
of procaspase-3 induced caspase-3 activation [38]. In
Fas-mediated apoptosis, Fas thiolation following caspase-
dependent Grx1 degradation resulted in the activation
of caspases-8 and -3 [39]. Molecular chaperones are an
interesting class of proteins that are readily S-glutathiolated
wherein thiolated proteins exhibited potentiation of chap-
erone activities, such as the correct folding of newly
synthesized polypeptides [6]. The activities of several S-
glutathiolatedmembersoftheglucose-relatedprotein(GRP)
family of proteins including GRP78, heat shock protein 60
(Hsp60), heat shock cognate 71-kDa protein, and Hsp90
were similarly increased by S-glutathiolation in diamide-
treated endothelial cells [40]. Remarkably, even endothelial
cytoskeletal reorganization can be modulated by protein S-
glutathiolation, notably that of actin and tubulin. Under
physiological conditions, S-glutathiolated actin (at Cys374)
inhibited F-actin polymerization, which was reversed by
EGF via actin deglutathiolation [41], consistent with a
dynamic role of actin assembly/disassembly in the biological
process of cell division and cell growth. Notably, actin-
glutathiolation also occurred under conditions of oxidative
stress [42]; in this instance, intracellular actin disassembly or
disrupted actin-junctional protein interactions would likely
mediate the loss of endothelial barrier function. A role for
S-glutathiolated annexin A2-actin interaction is currently
unknown.Similarly,whileS-glutathiolationofendothelialβ-
tubulin has been reported [40], the biological importance of
this modiﬁcation in endothelial barrier function remains to
be deﬁned.
1.4. GSH Regulation: Transcriptional Control of GCLc and
GCLmExpression. GCL-catalyzeddenovosynthesisiscentral
tothepreservationoftissueGSHbalance,particularlyduring
oxidative stress. GCL is a heterodimeric protein composed
of catalytic (GCLc) and modiﬁer (GCLm) subunits. The
GCLc subunit alone possesses all of the catalytic activities
of the enzyme; however, heterodimerization with the GCLm
subunit increases GCL activity (Vmax and Kcat), substrate
aﬃnity (Km) for glutamate and ATP, and the Ki for GSH
feedback inhibition [43]. Metabolic regulation of GCL is
mediatedbyproteinphosphorylationatserineandthreonine
moieties, which inhibits enzyme activity and transcriptional
control of GCL function is through the expression of the
catalytic and modulatory subunits.
1.4.1. Regulation of GCL Catalytic (GCLc) and Modiﬁer
(GCLm) Subunits. The promoters of GCLc and GCLm
subunits share common elements and coordinate transac-
tivation results in overall increase in subunit expression.
Key mediators of GCL expression are the redox sensitive
transcription factors, nuclear factor kappa B (NF-κB), Sp-1,
activator protein-1 and -2 (AP-1, AP-2), and nuclear factor
E2-related factor 2 (Nrf2) [44]. The promoter of the human
GCLc gene contains consensus binding sites for AP-1, NF-
κB, Nrf2, and for the antioxidant response (ARE) or elec-
trophile responsive (EpRE) elements [44]. A proximal AP-1
element was crucial for the transcription of GCLc induced
by oxidative stress [45] while NF-κB was essential in TNFα-
mediated increase in GCLc transcription either directly
or indirectly via transactivation of AP-1 sites through
induction of C-Jun expression [43]. Among the four AREs
in the human GCLc promoter, ARE4 was important in
the constitutive expression of hepatic GCLc induced by
β-naphthoﬂavone (β-NF) or cytochrome P450 2E1 [46,
47]. In macrophages, elevated GCLc expression caused by
homocysteine was mediated by ARE4 and the MERK-
ERK1/2 kinase pathway [48]. Involvement of the PI3 kinase
pathway was also described in adrenomedullin-induced
transcriptionalactivationoftheGCLcpromoter[49].Recent
studies from our laboratory demonstrated a role for Nrf2
in the constitutive and insulin-induced endothelial GCLc
expression [50]. Insulin-induced GCLc promoter activation
was ARE4 dependent [51]. Signiﬁcantly, the increase in
GCL activity and GSH synthesis via insulin signaling and
activation of the PI3K/Akt/mTOR/Nrf2/GCLc pathway pre-
vented hyperglycemia-induced endothelial apoptosis [52].
Interestingly, rat GCLc promoter exhibited only three AREs
in the 5 -ﬂanking region, of which ARE3 was involved in
Nrf2-dependent expression of GCLc [53], suggesting species
diﬀerences in ARE requirements for GCLc activation.
Constitutive or induced posttranslational phosphoryla-
tion of GCLc further contributes to GCL control. In contrast
to insulin and hydrocortisone, which induced GCLc gene
expression [17], stress hormones such as glucagon and
phenylephrine caused GCLc phosphorylation through acti-
vating the protein kinases, PKA, PKC, or Ca2+-calmodulin
kinase [54, 55]. Notably, GCLc phosphorylation decreased
GCLc activity.
The transcriptional regulation of GCLm is poorly under-
stood. Current evidence shows that the human GCLm
promoter also contained an ARE site that mediated Nrf2-
dependent GCLm upregulation induced by β-NF and lipid
peroxidation products [56, 57]. In rat liver, an ARE ele-
ment similarly mediated the basal and TNFα-induced of
the GCLm promoter activity [58]. Additionally, the rat
GCLm promoter has an AP-1 consensus site for constitutive
and tert-butylhydroquinone-induced GCLm expression. For
reasons yet unclear, NFκB-dependent GCLm expression
appeared to be linked to AP-1 activation within the GCLc
promoter [43], suggesting possible cross-talk between the
two promoters in subunit expression.
2. OxidativeChallenge and Endothelial
BarrierDysfunction
2.1. Inﬂuence of Reactive Oxygen Species (ROS). It is abun-
dantly clear that oxidative stress induced by ROS such as
O2
•−,H O
•,o rH 2O2 can elicit endothelial barrier dysfunc-
tion. Moreover, oxidative stress also increased intracellular
endothelial calcium concentration ([Ca2+]i) [59, 60]; in
pulmonary artery endothelial cells, the blockade of Ca2+
entry abolished oxidative stress-induced solute permeability
[61], indicating that oxidative stress was linked to elevated
[Ca2+]i, an important modulator of endothelial permeability
(Figure 1). In addition, oxidants like H2O2 were shown toInternational Journal of Cell Biology 5
increase the phosphorylation of myosin light chain kinase
[62], suggesting that ROS can alter endothelial contraction
and contribute to endothelial barrier dysfunction (Figure 1).
This means that oxidant modulation of the cytoskeletal
architecture of the endothelial monolayer could be central
to the loss of barrier integrity. Moreover, increased ROS
concentrations can decrease NO bioavailability through
chemical inactivation to form the powerful oxidizing agent,
peroxynitrite [63]. Tetrahydrobiopterin (BH4), a critical
cofactor for eNOS function, is a crucial target for oxidation
by peroxynitrite [64]. Signiﬁcantly, BH4 oxidation and
depletion were shown to induce eNOS uncoupling, a process
that was associated with increased O2
•− generation and
decreased NO production. In this regard, uncoupled eNOS
is akin to a dysfunctional O2
•− generating enzyme that
could contribute to endothelial oxidative stress and vas-
cular dysfunction. The uncoupling of eNOS has been
demonstrated in vitro a n di nh y p e r t e n s i v er a t( S H R )m o d e l s
of cardiovascular pathophysiology, such as angiotensin-II-
induced hypertension and diabetes [65].
Control of paracellular permeability in the endothelium
is a function of the intercellular endothelial adherens junc-
tions(AJ)andtightjunctions(TJ),acomplexstructurecom-
prised of speciﬁc junctional proteins. The cadherins, α-
catenin, and β-catenin proteins are components of the AJ,
while the transmembrane proteins, occludin, claudin, junc-
tion adhesion molecule, and the cytoplasmic accessory
zonulaoccludin(ZO-1,-2,and-3)proteinscomprisedtheTJ
[66]. H2O2-induced barrier disruption has been shown to
occur through rearrangement of endothelial cadherin and
β-catenin and the disruption of β-catenin/cytoskeletal as-
sociation [67], but the signaling events are unresolved.
However, activation of ERK1/ERK2 signaling and occludin
phosphorylation were shown to mediate the disorganization
ofoccludinandthedisruptionofoccludin-ZO-1interactions
on endothelial cell surfaces [68]. ROS activation of signaling
pathways, such as PKC, may further regulate the phospho-
rylation state of other AJ and TJ proteins. In this regard, a
reversal of thrombin-induced loss of the cadherin junctional
proteins, ρ-catenin, α-catenin, and p120, by PKC inhibitor
has been described [69].
2.2. Role of Carbonyl Stress. Carbonyl stress is the result
of enhanced reactive carbonyl species (RCS) production
and decreased carbonyl-scavenging capability, leading to
tissue accumulation of reactive dicarbonyl species, such as
methylglyoxal (MG). MG is produced from cellular gly-
colytic intermediates and can induce carbonyl stress through
irreversible reaction with free arginine residues of proteins
to form advanced MG-glycated end product (AGE) [70]
(Figure 1). The generation of protein carbonyls or protein-
glycated products could be a major problem in diabetic
neurovascular pathology. An MG-derived argpyrimidine
adduct has been detected in human lens and kidney and
in atherosclerotic lesions of diabetic patients [71–73], and
argpyrimidine-modiﬁed heat shock protein 27 (Hsp 27) was
shown to alter diabetic endothelial cell function [74]. More-
over, diabetes-associated hyperglycemia and MG-induced
modiﬁcation of the corepressor mSin3A gene were linked
to elevated angiopoietin-2 transcription in microvascular
endothelial cells [75]. Other evidence revealed that the
modiﬁcation of 20S proteasome by MG decreased protea-
somal chymotrypsin-like activity and impaired the CHIP
and chaperone-dependent quality control of the protein
[76], leading to the accumulation of toxic aggregates and
endothelialcelldeath.Further,MG-inducedglycationofvas-
cular basement membrane type IV collagen yielded hotspots
of arginine-derived hydroimidazolone residues at RGD and
GFOGER integrin-binding sites, causing endothelial cell
detachment, anoikis, and inhibition of angiogenesis [77].
The crosslinking of MG and amino acids was shown to
yield the O2
•− radical anion [78] that can be quenched by
O2
•− scavenger and membrane-permeable catalase [79]. Sig-
niﬁcantly, MG-derived ROS has important implications for
vascular and endothelial function. It is noteworthy that MG-
induced mitochondrial O2
•− generation stimulated eNOS
activity [79], while MG-mediated eNOS phosphorylation
(at ser1777) attenuated endothelial NO production [80],
suggesting that carbonyl stress modulation of endogenous
endothelial NO production is a complex process. In rat
carotid arterial endothelium MG was found to augment
AT1R-induced NADPH oxidase-derived mediated O2
•− and
H2O2 production, which increased Ang II-dependent vascu-
lar contraction [81]. Similarly, MG-derived ROS mediated
the oxidative and hyperglycemic stress-induced impairment
of endothelium-dependent vasorelaxation. This oxidative
stress response was attenuated by the overexpression of
glyoxalase I which promoted MG degradation [82]. In recent
studies, we found that MG-occludin glycation induced bar-
rier dysfunction of human brain microvascular endothelial
cells; surprisingly, MG-dependent endogenous ROS genera-
tion did not contribute majorly to barrier dysfunction. Our
study further revealed that the endothelial GSH status is a
determinant of barrier integrity by facilitating glyoxalase I-
catalyzed MG metabolism and thereby decreasing the avail-
ability of free MG (Li and Aw, unpublished data, Figure 1).
Moreover, GSH depletion signiﬁcantly promoted MG-
induced endothelial oxidative stress and cell apoptosis [25,
83].
Alteredcellmorphology,aberrantcytoskeletalrearrange-
ment, and ZO-1 loss were notable biological consequences
of glyoxal, another sugar-derived aldehyde product. Addi-
tionally, glyoxal also elicited mitochondrial dysfunction,
inhibition of DNA and cell replication, and cell cytotoxicity
through protein carbonyl formation [84]. Collectively, these
ﬁndings underscore the wide-ranging cellular eﬀects of
carbonyl stress on vascular endothelial function.
3.Endothelial Repairthrough
Proliferation and Growth
3.1. Biology of Cell Cycle Control. Cell cycle control is crucial
for proper postdamage endothelial repair and growth. The
mammalian cell cycle is characterized by a quiescent G0
phase of nondividing cells followed by cell entry into the cell
cycle at G1 and progression through the S, G2, and M phases6 International Journal of Cell Biology
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Figure 2: Nuclear glutathione cycle and associated redox changes during cell cycle progression. A nuclear GSH cycle is established during
cell cycle progression that involves the dynamic partitioning of cellular GSH between the nuclear and cytosolic compartments. Cell entry
into the cycle in early G1 is associated with sequestration of GSH into the nucleus (A). At this stage of cell cycle initiation, the nuclear-
to-cytosol (n/c) GSH ratio approximates 4. The transient decrease in cytosolic GSH releases feed-back inhibitory eﬀect of GSH on GCL
activity and triggers de novo GSH synthesis, a process that continues until the feedback control is reestablished. Sequestered intranuclear
GSH exists in the reduced form or bound to nuclear proteins, which together changes the GSH/GSSG redox potential (Eh)i nf a v o ro fg e n e
transcription and cell cycle-associated DNA synthesis/replication. Free GSH functions in antioxidant defense that protects against oxidative
DNA damage during DNA replication. As yet unclear, free GSH may be regenerated via deglutathiolation of thiolated nuclear proteins,
likely catalyzed by Trx1 and/or Grx1. The dissolution of the nuclear envelope in the prometaphase and cytokinesis (cell cycle exit) induces
nuclear-to-cytosol GSH export (B) resulting in equal GSH distribution (n/c = 1) in the two compartments in the newly divided cells. Redox-
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glutathione, GSSG: glutathione disulﬁde, GCL: γ-glutamate cysteine ligase; n/c: nuclear-to-cytosol, Trx1: thioredoxin1, Grx1: glutaredoxin
1, and Cdk: cyclin-dependent kinase.
in response to environmental or cellular cues that over-
come the biological constraint of a mitotic block [20].
DNA replication takes place during the S phase, and
accurate replication commits cell progression into the M
phase while aberrant DNA replication induces transient
G2 arrest that allows for DNA repair [85]. Failure of
DNA repair initiates cell cycle withdrawal and permanent
senescence. Cell progression through the cell division cycle
is governed by regulatory checkpoints controlled by speciﬁc
serine/threonine cyclin-dependent kinases (CDKs) and their
respective cyclin subunits. Speciﬁcally, the checkpoints for
cell transitions from G0/G1 to S, late G1 to early S, S to G2,
and G2 to M are, respectively, regulated by D-type cyclin
D1, D2 and associated with CDK4-6, cyclin E1/CDK2 com-
plex, cyclin A/CDK2 kinase complex, and cyclin B1/CDK1
kinase complex in association with Cdc25 phosphatase [86]
(Figure 2).
3.2. Glutathione and Cell Cycle Regulation. The progres-
sion of cells through the cell cycle has been linked to
dynamic changes in the intracellular redox environment
particularly that of the GSH/GSSG redox couple from a
more oxidized state prior to cell cycle initiation to a more
reduced state throughout cell cycle until cell cycle exit after
prometaphaseandcytokinesis(Figure 2).Speciﬁcally,studies
have documented that cell exit from the quiescent stage
at G0/early G1 and entry into cell cycle was characterized
by a relatively more oxidizing milieu [87, 88] than that
during progression from G1 through S to G2/M [87, 89].
The redox status of cysteine residues of cell cycle regulatoryInternational Journal of Cell Biology 7
proteins and their functions were highly sensitive to the
intracellular redox environment, which is impacted by cellu-
lar production and/or removal of ROS [86]. For example, in
actively dividing cells, redox-dependent activation of speciﬁc
cyclin/CDKs complexes by locally produced ROS allowed for
checkpoint bypass at the G1 restriction point or at late G1
to S transition [7, 14, 90]. Similarly, growth-factor-mediated
ROSproduction and redox regulation ofp16, p27, and cyclin
D1, which drove terminally diﬀerentiated cells into cell cycle
[91, 92], governed the reentry of quiescent cells into the cell
cycle [91, 92]. E2F, pRB, MAP kinase, Cdc25 phosphatase,
and cyclin are other important cell cycle proteins shown
to undergo redox changes and/or modiﬁcations during cell
cycle progression [90, 93–95].
A role for ROS in mitogenic signaling is underscored by
the ﬁnding that treatment of serum-starved cells with the
thiol antioxidant, N-acetylcysteine (NAC), elicited cell cycle
arrest at G1,ad e l a yo fG 0 to G1 progression that correlated
withdefectiveredox control[92]. Interestingly, during expo-
nential growth of cultured mouse embryonic ﬁbroblasts,
NAC treatment arrested cells at the G1 to S transition but
allowed cell transit through the S, G2, and M phases [96],
indicating that redox control at the early event at G1
governed cell progression from G1 to S. An increase in
MnSOD activity was implicated in NAC-induced inhibition
of G1 to S entry [90]. Collectively, these studies illustrate the
importanceofROSinmitogenicsignalingduringcellcycle,a
redoxprocessthatappearstobecoordinatedthroughdeﬁned
cellular mechanisms for ROS generation and elimination. A
reduced intracellular redox environment protected genomic
DNA from oxidative damage upon breakdown of the nuclear
envelope [89] and was therefore essential to enhance DNA
synthesis during cell transition from G1 to G2/M. Early
accumulation of soluble thiols at the mitotic spindle was
observed during mitosis in sea urchin eggs [97]. Similarly
a graduation of low to high GSH content was associated
with the transition of Chinese hamster ovary ﬁbroblasts
through G1 to S to G2/M [89], consistent with a well-deﬁned
dynamics of redox changes in the intracellular environment
during cell cycle.
Intracellular redox homeostasis is maintained by the
thiol/disulﬁde redox systems of GSH/GSSG, thioredoxin
(Trx/TrSS), and cysteine (Cys/CySS). The product of reduc-
ing potential and reducing capacity of the redox couples
determined the cellular redox environment, which in most
cells are largely governed by that of the GSH/GSSG couple
[4]. Indeed, the cellular GSH/GSSG redox status provides a
good quantitative indicator of the intracellular redox state,
often expressed as the redox potential, Eh. Under physio-
logical conditions, Eh for GSH/GSSG, as calculated by the
Nernst equation, is between −260mV and −200mV [15].
Notably, a change in GSH/GSSG Eh from a reduced value of
∼260mV to an oxidized value of −170mV was associated
with phenotypic cell transition from proliferation to growth
arrest and apoptosis [15]. As discussed in Section 1.2.1,
speciﬁcity of redox signaling and independent redox regu-
lation of the functions of single proteins or protein sets are in
part attributed to the existence of distinct compartments of
GSH within the subcellular organelles.
Recent evidence suggests that the dynamic cytosol-to-
nuclear GSH distribution was a crucial factor in cell cycle
progression in that nuclear GSH accumulation provided an
intranuclear redox environment that enabled proper regula-
tion of redox signaling events during the various stages of
the cell cycle [13]. A novel concept of a nuclear GSH cycle
that operated during cell cycle has been proposed [98]a s
illustratedinFigure 2.Accordingtothishypothesis,GSHwas
recruited and sequestrated into nucleus in early G1 phase,
likely through a BcL-2-dependent import mechanism [99].
Increasedcytosolic-to-nuclearGSHtranslocationtransiently
caused GSH imbalance within the cytosol that initiated de
novo GSH synthesis, resulting in progressive increases in
the total cytosolic GSH pool. Cell transition through G2/M
and the dissolution of the nuclear envelope during mitosis
enabled the reequilibration of the cytosolic and nuclear GSH
pools, and this return to a pre-cell cycle nuclear-to-cytosolic
GSH ratio of 1 to 1 was maintained in non-proliferating cells
at G0/G1. It was further proposed that it was the transient
decrease in cytosolic GSH that promoted early G1 signaling.
Moreover, the increased GSH presence in the nucleus during
the S phase coincided with the activation of DNA replica-
tion as evidenced by elevated S-glutathiolation of histones,
telomerase, and polyADP ribose polymerase [13, 100].
Additionally, DNA synthesis and replication could be further
facilitated by GSH-dependent reorganization of the nuclear
matrix and chromatin structure [101]. The details of GSH
control of cell cycle checkpoints during endothelial cell
proliferation are sketchy and are the subjects of current
investigation in our laboratory.
3.3. Glutathione Disruption and Implications for Endothelial
Growth and Repair. As an organ that is highly dependent
on oxidative metabolism for its energy needs, the brain is
susceptible to tissue GSH imbalance and oxidative damage
mediated by increased formation of free radical species and
lipid peroxidation [102, 103]. Given the location of the
BBB at the interface between brain parenchyma and systemic
blood, the endothelial monolayer is easily exposed to the
oxidizing conditions of elevated ROS or RCS associated with
various pathological states (Section 4 below). Additionally,
an often decreased tissue or systemic GSH level under these
diseased states would enhance oxidative damage to the
vascular endothelium and the consequent loss of vascular
integrity will have important implications for cerebral
homeostasis. The enzyme γ-glutamyl transpeptidase (γ-GT)
is regarded as a marker of BBB integrity in the mammalian
brain. It is noteworthy that γ-GT levels were lowest in the
more primitive regions of the brain and highest in the
more specialized regions of the brain [104], the reason of
which is yet unknown. Importantly, within the brain, the
microvesicular fractions exhibited signiﬁcantly higher γ-GT
activity than the neuronal or glial fractions, consistent with
a microvesicular localization of the enzyme [104]. However,
γ-GT activity in type I cells (“cobblestone” phenotype)
increased 10–12-fold after glial stimulation, indicating a
role for type I cells in BBB function as well [105]. Equally
notable was the ﬁnding that membrane-associated γ-GT8 International Journal of Cell Biology
activityintheendotheliumofcapillarieswashigherthanthat
in larger vessels in the brain, implying that cerebral small
vessel endothelial monolayers will likely be more sensitive
to ﬂuctuations in the plasma GSH levels in terms of both
susceptibility to injury and eﬃciency of repair. Further-
more, given that γ-GT can catalyze the metabolism of not
only GSH but also S-nitrosoglutathione (GSNO), cerebral
microvascular γ-GT function could be pivotal in mediating
the bioactivity of GSNO and/or NO (Section 4.2).
The ﬁndings that GSH levels in endothelial cells in
culture increased during the lag phase, were elevated during
the initial exponential growth phase, and then fell as cells
become conﬂuent [106] suggest that systemic GSH inter-
ruption would alter endothelial growth. Our recent stud-
ies in human microvascular endothelial cells showed that
inhibition of GSH synthesis and GSH depletion elicited a
delayed S-to-G2transition reﬂected in a lengthening of the
cell cycle S-phase resident time (Busu and Aw, unpublished),
in agreement with previous observations [107]. Signiﬁcantly,
cellular GSH depletion was largely conﬁned to the cytosolic
pool while the nuclear GSH compartment remained rela-
tively unchanged. Somewhat surprisingly, delayed S-to-G2
transition remained evident for 6h despite the restoration
of cytosolic GSH synthetic capacity and near normalization
of basal cellular GSH levels (Busu and Aw, unpublished),
consistent with a signiﬁcant time lag between restored
cellular redox balance and recovery of normal cell cycle
activity. The reason for this temporal dissociation is unclear
and is currently under investigation in our laboratory. What
is clear, however, is that through perturbing cell cycle
events, a disruption in cellular GSH such as that occuring
during oxidative or carbonyl stress could delay endothelial
proliferation and tissue repair following oxidative damage to
the endothelium, a deleterious scenario for brain function in
cerebrovascular and neurodegenerative disorders.
4.Pathological ImplicationsofImpaired
GlutathioneinNeurovascularDisease States
4.1. Neurovascular Pathology of Diabetes. Increased BBB per-
meabilityhasbeendemonstratedinpatients withtypeIIdia-
betes [108] and in the streptozotocin- (STZ-) induced type
I diabetic experimental rat model [109]. Elevated activities
of plasma metalloproteinases 2 and 9 were implicated in the
loss of tight junctional proteins (occludin, claudin-5, ZO-1,
andJAM-1)andBBBfailure[110].Interestingly,thereceptor
for AGE (RAGE) was upregulated during diabetes [111],
suggesting that increased plasma-to-cellular MG uptake
and enhanced GSH-dependent intracellular MG catabolism
couldprovideameanstoattenuatetheelevatedsystemicMG
levels associated with the diabetic state. BBB disruption was
notable during diabetic ketoacidosis wherein neurovascular
inﬂammation, accompanying CCL-2 chemokine expression,
NF-κB activation, and nitrotyrosine formation were likely
contributors to the attenuated BBB integrity and increased
barrier permeability [112]. In STZ-induced diabetic rats,
BBB function was improved by the administration of growth
hormone and insulin [113, 114] .O u rr e c e n ts t u d i e sd e m o n -
stratedthatinsulin-mediatedprotectionofhumanmicrovas-
cularendothelial cellsagainstMG-induced apoptosis wasthe
result of increased intracellular GSH through activation of
the insulin-PI3K/Akt/mTOR/Nrf2/GCLc signaling pathway
[50, 52].
It is well known that diabetes is associated with hyper-
glycemia, elevated oxidative and carbonyl stress, and low
tissue and plasma levels of GSH [115–120], conditions
that complicate the diabetic state, which would lead to
further exacerbation of GSH loss. Thus, mechanisms that
promote neurovascular GSH status or those that attenuate
oxidative and/or carbonyl stress could preserve endothelial
barrier function. A viable approach could involve activation
of insulin signaling to maintain cellular GSH balance
and support GSH-dependent attenuation of oxidative or
carbonyl stress mediated by ROS or MG [25, 51, 52, 121].
Furthermore, increasing GSH protection of redox sensitive
thiols of membrane proteins, including those of the AJ or TJ,
could preserve the functional integrity of the endothelium.
The question of whether acute or chronic GSH therapy
would be eﬀective in abrogating systemic hyperglycemia-
linked oxidative and carbonyl stress and mitigate diabetes-
associated BBB dysfunction remains an open question that
warrants further investigation.
4.2. Microvascular Dysfunction in Stroke. Stroke is a cere-
brovascular disorder wherein a blood clot or interrupted
blood ﬂow to a region of the brain leads to a rapid loss of
brain function. Signiﬁcantly, a lack or delayed ﬂux of oxygen
and glucose to the brain will result in neuronal death and
brain damage. Clinical studies have shown that subjects at
risk for stroke exhibited low tissue GSH levels and decreased
GSH-to-GSSG ratio and that the restoration of normal
cerebral GSH balance could be as long as 72h after the
ischemic insult [122, 123]. Importantly, acute ischemic
stroke was associated with elevated oxidative stress, a major
contributor to immediate and delayed ischemic brain injury
andchangesintheparenchymalGSHredoxstatus[124,125].
An increase in free radical production during acute cerebral
ischemia can arise from multiple sources including stimu-
lation of N-methyl-D-aspartate receptors [126], mitochon-
drial dysfunction [127], activation of neuronal NO synthase
(NOS) [128, 129], autooxidation of catecholamines, and
metabolism of free fatty acids [130]. The activation and
migration of inﬂammatory cells, such as neutrophils, further
contributed to O2
•− and H2O2 generation [130].
The restoration of endothelial integrity after thrombotic
or hemorrhagic stroke is crucial to preserving BBB func-
tion and neurovascular homeostasis. The proliferation of
endothelial cells adjacent to the lesion or injury site is a
pivotal step. Given the role of GSH in cell proliferation
(Section 3), maintaining cellular GSH balance is therefore
essential for postdamage endothelial repair and wound
healing. S-nitrosoglutathione (GSNO) is an important phys-
iological metabolite produced by the reaction of NO with
GSH [131] that is involved in NO storage and release
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for GSNO (Km of 0.4mM) was comparable to other γ-
glutamyl substrates [132], suggesting a physiological role
for γ-GT-in GSNO metabolism. Whether high micromolar
concentrations of GSNO are achievable in cells remains
uncertain. However, recent studies demonstrated that, at
least in plasma, GSNO levels are likely to be higher than
previously reported due to the presence of exogenous γ-GT
[133], further underscoring the signiﬁcance of the enzyme in
modulating GSNO levels and bioactivity.
Reportedly, GSNO functions in cellular signaling [134,
135] and protection of the central nervous system (CNS)
against excitotoxicity, inﬂammation, and ROS [136, 137].
Notably, GSNO protection against peroxynitrite-induced
oxidative stress is severalfold more potent than GSH [138].
GSNO-mediated CNS protection against inﬂammation
appeared to be through suppressing iNOS induction and
promoting eNOS expression, and maintaining cerebral
blood ﬂow [139]. The anti-inﬂammatory activity of GSNO
in downregulating iNOS was mediated by inhibition of NF-
κBactivationanddecreasedexpressionofICAM-1andED-1.
Additionally, the expression of ZO-1 and occludin at
endothelial tight junctions was enhanced by GSNO treat-
ment [140]. Unlike conventional NO donors that mediate
quick NO release, GSNO elicits slow NO release that was
implicated in neurovascular protection against ischemia
reperfusion [141]. In addition to γ-GT, S-nitrosoglutathione
reductase(GSNOR),whichcatalyzesthereductionofGSNO,
has been shown to be an important regulator of the
endogenous GSNO levels and NO bioactivity. The patho-
physiological role of GSNOR in SNO signaling and NO
bioactivity in the regulation of vascular tone is incompletely
understood; recent evidence suggests that GSNOR regulates
airway SNO levels in cell signaling [142] and protects against
nitrosative stress and cancer risk in human lung [143]. This
notwithstanding, it remains unclear whether therapeutic
strategies involving exogenous GSH and/or NO supplemen-
tation during neurovascular inﬂammatory conditions, such
as stroke, would be clinically eﬃcacious in the short term in
attenuating the oxidative burden and protecting the BBB, or
in the long term in reducing brain edema and tissue damage.
5.SummaryandPerspective
The integral function of the microvascular endothelium
underpins cerebrovascular homeostasis. ROS- and/or RCS-
induced endothelial dysregulation is an underlying concern
in barrier failure, and, as such, much research has focused on
the use of antioxidants as a strategy to attenuate oxidative or
carbonyl stress and restore monolayer function. The ﬁnding
that GSH, a major cellular antioxidant, is able to aﬀord
cytoprotection supports the notion that antioxidant therapy
is important in endothelial barrier preservation. In past
years, more recent conceptual advances in redox cell biology
have uncovered a fundamental role of GSH in signal trans-
duction and redox signaling in cellular functions. Moreover,
the ﬁnding that distinct pools of GSH exist in subcellular
organelles that allow for independent redox regulation
has revolutionized our thinking of GSH-dependent redox
mechanisms in controlling metabolic processes. One such
biological process is that of cell proliferation. In the con-
text of enhanced endothelial proliferation and self-repair
surrounding lesion sites in response to systemic cues, for
example, growth factors, little is known of a role for
GSH. The dynamics of cytosol-to-nuclear GSH distribution
appears to be pivotal in governing cell cycle responses. The
notion that cell proliferation and growth can be a relevant
biological process for monolayer repair/restitution following
endothelial injury in much the same way as epithelial cell
restitution/proliferationrestorespostinjuredepitheliumsug-
gests exciting new avenues for future research in endothelial
biology. Importantly, an understanding of GSH control of
endothelial cell proliferative potential under diﬀerent oxi-
dizing conditions and plasma GSH levels will expand our
perspective for future development of therapeutic strategies.
Targeting endothelial restoration after oxidative insult and
tissue damage is likely to be clinically relevant to the neu-
rovascular disorders of diabetes and stroke and additionally
could have broader implications for neurodegenerative and
neurological disorders as well.
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